Shares of AveXis Inc. (NASDAQ:AVXS) traded up 2.2% during trading on Monday . The company traded as high as $36.45 and last traded at $35.70, with a volume of 83,264 shares. The stock had previously closed at $34.92.

A number of analysts have recently commented on the stock. Zacks Investment Research upgraded shares of AveXis from a “sell” rating to a “hold” rating in a research note on Thursday, June 9th. Jefferies Group lowered shares of AveXis from a “buy” rating to a “hold” rating and lifted their price target for the stock from $39.00 to $42.00 in a research note on Wednesday, June 22nd. They noted that the move was a valuation call. Wells Fargo & Co. assumed coverage on shares of AveXis in a research note on Friday. They issued a “market perform” rating for the company. Goldman Sachs Group Inc. lifted their price target on shares of AveXis from $28.00 to $47.00 and gave the stock a “buy” rating in a research note on Friday, May 13th. Finally, Chardan Capital assumed coverage on shares of AveXis in a research note on Monday, March 28th. They issued a “buy” rating and a $60.00 price target for the company. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. AveXis has a consensus rating of “Buy” and an average price target of $43.80.

The firm’s market capitalization is $824.56 million. The stock’s 50 day moving average is $40.69 and its 200 day moving average is $30.45.

AveXis (NASDAQ:AVXS) last issued its earnings results on Thursday, May 12th. The company reported ($1.24) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.35) by $0.89. Equities research analysts predict that AveXis Inc. will post ($3.90) EPS for the current fiscal year.

AveXis, Inc, formerly Biolife Cell Bank, Inc, is a clinical-stage gene therapy company. The Company operates through developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.